Call for Abstracts
*All dates are in Japan Standard Time (JST/UTC+9)
Submission Deadline
| Abstract submission | 12:00 PM, Thursday, October 2, 2025 - Wednesday, December 17, 2025 |
Presentation type
FujiRetina 2026 is accepting poster presentation only.
All presenters are requested to come to the venue and affix their posters themselves.
All presenters are requested to come to the venue and affix their posters themselves.
Category
Please select one option from each section below:
Section 1: Field Type
| A | Medical | B | Surgical |
|---|
Section 2: Specialty Category
Select an appropriate category from the following list.
Select an appropriate category from the following list.
| 01 | Basic medicine | 09 | Central serous chorioretinopathy |
|---|---|---|---|
| 02 | Diagnosis/Examination | 10 | Age-related macular degeneration |
| 03 | Retinal detachment | 11 | Retinal dystrophies |
| 04 | Diabetic retinopathy | 12 | Vitrectomy |
| 05 | Retinal vein occlusion | 13 | Treatments other than surgery |
| 06 | Pathologic myopia | 14 | Low vision |
| 07 | Macular hole/Epiretinal membrane | 15 | Other categories |
| 08 | Macular edema |
Submission Guidelines
FIRST (PRESENTING) AUTHOR
- 1. The first author will be the presenting author. The first (presenting) author is expected to register and pay the full registration fee, prepare the presentation and attend the conference.
- 2. Please provide an accurate email address of the first (presenting) author. Abstract submission results and abstract-related correspondence will be sent to the first author by email.
- 3. The first author cannot be the first author of another abstract.
CO-AUTHOR(S)
- A maximum of 12 co-authors are allowed for each abstract. Type in the names and affiliations as you would like them to appear in published materials.
ABSTRACT TITLE
- The title must not exceed 100 characters including spaces.
CONTENTS
- It is advised to include PURPOSE, METHODS, RESULTS and CONCLUSIONS.
The abstract must not exceed 250 words.
Do not include graphs, tables, images, and references in the abstract.
Declaration of conflict of interest is mandatory for all authors (See below for details).
On the abstract submission form, please select whether you have obtained the approval of the ethics committee, e.g. IRB, or if it is not necessary. This does not need to be stated in the abstract text.
Regarding the approval of the animal research and ethics committee, e.g. IACUC, please select whether you have obtained the approval of the committee or if it was not necessary, on the abstract submission form. The author is not required to mention it in the abstract body.
On the abstract submission form, please select whether you have obtained an informed consent or if it is not necessary. This does not need to be stated in the abstract text.Travel Grant
FujiRetina encourages non-Japanese overseas ophthalmologists to submit abstracts. Six abstracts will be selected as travel grant recipients by the Organizing Committee. 700 USD will be awarded to the first author of the submitted abstract. When selecting the appropriate category, please also select the travel grant application at the same time.
Note
- The travel grants will be presented to the grant winners after their abstract presentations at the meeting. All travel grant recipients must attend FujiRetina in person.
- Travel grant recipients are responsible for making their own arrangements for transportation to the venue and accommodation during the meeting period.
- FujiRetina will not provide any stipends or reimbursements beyond 700 USD.
- Results of the awards will be announced by email in early February 2026.
- Practicing physicians and trainees are all eligible for the travel grants.
Best Poster Awards
These awards are given to the three best posters presented at the meeting.
Poster winners will be recognized publicly at the Gala Party on March 28, 2026.
Poster winners will be recognized publicly at the Gala Party on March 28, 2026.
Notification of Receipt of Abstracts
A notification will be sent for registration confirmation to the registered email. If you do
not receive a notification at the registered email within 24 hours, please inform the
secretariat. For submissions, notification of acceptance or rejection will be sent to the
registered email in early February 2026 .
If payment of the registration fee for the FujiRetina 2026 is not completed by the Author Registration Deadline, which will be announced later, your abstract will be considered as having been withdrawn. We will inform you of the payment details in our notification email.
If payment of the registration fee for the FujiRetina 2026 is not completed by the Author Registration Deadline, which will be announced later, your abstract will be considered as having been withdrawn. We will inform you of the payment details in our notification email.
Conflict of Interest
Authors have to report any conflict of interest at the beginning of any presentation at
FujiRetina. If the presentation is accepted, the category of conflict of interest and
company names must be disclosed in the poster for presentation based on “the rules for
conflict of interest of Japanese Ophthalmological Society."
A. Presentations to Which These Rules are Applicable
These rules are applicable to all presentations, including those in Co-Sponsored Seminars, Free Paper, Panel Discussion, Poster presentation, etc.B. Report on Conflict of Interest at Abstract Submission
Report on the potential conflict of interest with companies within the last three years no matter whether it's concerned with or without the content of your presentation. If conflict of interest is “present," enter the category, class and company names after each author's name in the entry field of “Conflict of Interest" on the abstract submission form. If conflict of interest is absent, enter “category N." Confirm the declaration is correct prior to the registration. Categories and classes are as follows.1. Categories
F (Financial Support):
In the case where research expenses are supported or free research materials (including devices) or services (including sample measurements) are provided by companies (*) through the organization to which the author belongs.
(*) Companies denote both related companies and competitor companies. This is also the case for all subsequent categories.
In the case where research expenses are supported or free research materials (including devices) or services (including sample measurements) are provided by companies (*) through the organization to which the author belongs.
(*) Companies denote both related companies and competitor companies. This is also the case for all subsequent categories.
I (Personal Financial Interest):
In the case where the author is an investor in a company related to the chemicals and materials (including devices) used and services are provided.
In the case where the author is an investor in a company related to the chemicals and materials (including devices) used and services are provided.
E (Employee):
In the case where the author is an employee of an interested company.
In the case where the author is an employee of an interested company.
C (Consultant):
In the case where the author is currently, or was within the past three years, a consultant of an interested company.
In the case where the author is currently, or was within the past three years, a consultant of an interested company.
P (Patent):
In the case where the author holds a patent or is in the process of applying for a patent.
In the case where the author holds a patent or is in the process of applying for a patent.
R:
In the case where the author receives rewards (*) or travel expenses from a company related to the chemicals and materials (including devices) used and services provided.
(*) Rewards include salaries, travel fees, intellectual property rights, royalties, honoraria, shares, stock options, consultancy fees, lecture fees, expenses as a member of advisory committees and review panels, etc.
In the case where the author receives rewards (*) or travel expenses from a company related to the chemicals and materials (including devices) used and services provided.
(*) Rewards include salaries, travel fees, intellectual property rights, royalties, honoraria, shares, stock options, consultancy fees, lecture fees, expenses as a member of advisory committees and review panels, etc.
2. Class
Ⅰ．0 yen
Ⅱ．From 1 to less than 500,000 yen
Ⅲ．From 500,000 to 5,000,000 yen
Ⅳ．Over 5,000,000 yen
*Conflict of interest should be disclosed for the fiscal year during the previous three years when the author received the largest sum of money.
Ⅱ．From 1 to less than 500,000 yen
Ⅲ．From 500,000 to 5,000,000 yen
Ⅳ．Over 5,000,000 yen
*Conflict of interest should be disclosed for the fiscal year during the previous three years when the author received the largest sum of money.
C. Disclosures in the Abstract and Slide Decks
Abstract:
The presence or absence of conflict of interest to be disclosed for the author
(including co-authors) will be automatically shown at the end of the abstract,
according to “the detailed rules of the standard for disclosure in the Japanese
Ophthalmological Society." For categories F, C and R, only class IV (over
5,000,000 yen) will be corresponded to “presence".
Slide and Poster:
If the authors have to disclose any conflict of interest, the category and company names* should be described after the authors' names in the second slide and at the end of the poster. For categories F, C and R, only class IV (over 5,000,000 yen) should be disclosed.
* In the case of "Category P" (the author holds a patent or is in the
process of applying for a patent), the company name does not need to
describe.
If all authors do not have any conflict of interest to disclose, there will be a statement to the effect, “there is no conflict of interest to be disclosed".
If all authors do not have any conflict of interest to disclose, there will be a statement to the effect, “there is no conflict of interest to be disclosed".
Personal Information Protection
"Names" and "contact addresses" provided to us at registration for the meeting shall be
used for the purpose of contact from the secretariat, notification of acceptance or
rejection, and any information related to the presentation. In addition, the
“presenters' names," “affiliation names," “title" and “abstract text" shall be used for
publication in the program/proceedings and on the website, but not for other purposes.
The registration process for applications has been commissioned to c/o JTB Communication
Design, Inc. in order to facilitate management operations.
Inquiries
Secretariat of FujiRetinac/o JTB Communication Design, Inc.,
JTB Bldg. 8F, 2-1-25 Kyutaromachi, Chuo-ku, Osaka 541-0056, Japan
E-mail: fujiretina@jtbcom.co.jp